Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: A systematic review

Addiction

Volumn 103, Issue 8, 2008, Pages 1242-1257

  Malta, Monica ^a   Strathdee, Steffanie A ^b   Magnanini, Monica M F ^c   Bastos, Francisco I ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Adherence; AIDS; Antiretroviral therapy; Drug use; HAART; HIV; Methadone maintenance therapy; Psychosocial support; Systematic review

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; DEPRESSION; DISEASE ASSOCIATION; DRUG USE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; PATIENT CARE; PATIENT COMPLIANCE; REVIEW; SOCIAL SUPPORT; SYSTEMATIC REVIEW;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, VIRAL; DRUG USERS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NEEDS ASSESSMENT; PATIENT EDUCATION AS TOPIC;

EID: 47549096474     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2008.02269.x     Document Type: Review

References (65)

1. Mannheimer S. B., Matts J., Telzak E., Chesney M., Child C., Wu A. W. et al. Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. AIDS Care 2005 17 : 10 22.
2. Altice F. L., Mostashari F., Friedland G. H. Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr 2001 28 : 47 58.
3. Ferguson T. F., Stewart K. E., Funkhouser E., Tolson J., Westfall A. O., Saag M. S. Patient-percieved barriers to antiretroviral adherence: associations with race. AIDS Care 2002 14 : 607 17.
4. Paterson D. L., Swindells S., Mohr J., Brester M., Vergis E. N., Squier C. et al. Adherence to protease inhibitor therapy and outcomes in patientswith HIV infection. Ann Intern Med 2000 133 : 21 30.
5. Bangsberg D. R., Hecht F. M., Charlebois E. D., Zolopa A. R., Holodniy M., Sheiner L. et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000 14 : 357 66.
6. Bangsberg D. R., Charlebois E. D., Grant R. M., Holodniy M., Deeks S. G., Perry S. et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 2003 17 : 1925 32.
7. Bangsberg D. R., Perry S., Charlebois E. D., Clark R. A., Roberston M., Zolopa A. R. et al. Nonadherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001 15 : 1181 3.
8. Wood E., Hogg R. S., Yip B., Harrigan P. R., O'Shaughnessy M. V., Montaner J. S. Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy? AIDS 2003 17 : 711 20.
9. Wood E., Montaner J. S., Bangsberg D. R., Tyndall M. W., Strathdee S. A., O'Shaughnessy M. V. et al. Expanding access to HIV antiretroviral therapy to marginalised populations in the developed world. AIDS 2003 17 : 2419 27.
10. Bassetti S., Battegay M., Furrer H., Rickenbach M., Flepp M., Kaiser L. et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV cohort study. J Acquir Immune Defic Syndr 1999 21 : 114 19.
11. Celentano D. D., Vlahov D., Cohn S., Shadle V. M., Obasanjo O., Moore R. D. Self-reported antiretroviral therapy in injection DU. JAMA 1998 280 : 544 6.
12. Celentano D. D., Galai N., Sethi A. K., Shah N. G., Strathdee S. A., Vlahov D. et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection DU. AIDS 2001 15 : 1707 15.
13. Wang C., Vlahov D., Galai N., Bareta J., Strathdee S. A., Nelson K. E. et al. Mortality in HIV-seropositive versus seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis 2004 190 : 1046 54.
14. World Health Organization/Joint United Nations Programme on HIV/AIDS (WHO/UNAIDS). 2007 Report on the Global AIDS Epidemic. Geneva : WHO and UNAIDS 2007.
15. Inciardi J. A., Surratt H. L. Drug use, street crime, and sex-trading among cocaine-dependent women: implications for public health and criminal justice policy. J Psychoact Drugs 2001 33 : 379 89.
16. Latkin C. A., Knowlton A. R., Sherman S. Routes of drug administration, differential affiliation, and lifestyle stability among cocaine and opiate users: implications to HIV prevention. J Subst Abuse 2001 13 : 89 102.
17. Wensing A. M., van de Vijver D. A., Angarano G., Asjo B., Balotta C., Boeri E. et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005 192 : 958 66.
18. Vlahov D., Celentano D. D. Access to highly active antiretroviral therapy for injection DU: adherence, resistance, and death. Cad Saude Publica 2006 22 : 705 18.
19. Wainberg M. A., Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998 279 : 1977 83.
20. Escoto-Delgadillo M., Vazquez-Valls E., Ramirez-Rodriguez M., Corona-Nakamura A., Amaya-Tapia G., Quintero-Perez N. et al. Drug-resistance mutations in antiretroviral-naive patients with established HIV-1 infection in Mexico. HIV Med 2005 6 : 403 9.
21. Lucas G. M., Gebo K. A., Chaisson R. E., Moore R. D. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS 2002 16 : 767 74.
22. Crystal S., Sambamoorthi U., Moynihan P. J., McSpiritt E. Initiation and continuation of newer antiretroviral treatments among Medicaid recipients with AIDS. J Gen Intern Med 2001 16 : 850 9.
23. Turner B. J., Laine C., Cosler L., Hauck W. W. Relationship of gender, depression, and health care delivery with antiretroviral adherence in HIV-infected DU. J Gen Intern Med 2003 18 : 248 57.
24. Arnsten J. H., Demas P. A., Grant R. W., Gourevitch M. N., Farzadegan H., Howard A. A. et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected DU. J Gen Intern Med 2002 17 : 377 81.
25. Arnsten J. H., Demas P. A., Farzadegan H., Grant R. W., Gourevitch M. N., Chang C. J. et al. Antiretroviral therapy adherence and viral suppression in HIV-infected DU: comparison of self-report and electronic monitoring. Clin Infect Dis 2001 33 : 1417 23.
26. Wagner G. Placebo practice trials: the best predictor of adherence readiness for HAART among DU? HIV Clin Trials 2003 4 : 269 81.
27. McNabb J., Ross J. W., Abriola K., Turley C., Nightingale C. H., Nicolau D. P. Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clin Infect Dis 2001 33 : 700 5.
28. Hinkin C. H., Barclay T. R., Castellon S. A., Levine A. J., Durvasula R. S., Marion S. D. et al. Drug use and medication adherence among HIV-1 infected individuals. AIDS Behav 2007 11 : 185 94.
29. Altice F. L., Mezger J. A., Hodges J., Bruce R. D., Marinovich A., Walton M. et al. Developing a directly administered antiretroviral therapy intervention for HIV-infected DU: implications for program replication. Clin Infect Dis 2004 38 : S376 87.
30. Haug N. A., Sorensen J. L., Lollo N. D., Gruber V. A., Delucchi K. L., Hall S. M. Gender differences among HIV-positive methadone maintenance patients enrolled in a medication adherence trial. AIDS Care 2005 17 : 1022 9.
31. Arnsten J. H., Li X., Mizuno Y., Knowlton A. R., Gourevitch M. N., Handley K. et al. Factors associated with antiretroviral therapy adherence and medication errors among HIV-infected injection drug users. J Acquir Immune Defic Syndr 2007 46 : S64 71.
32. Purcell D. W., Metsch L. R., Latka M., Santibanez S., Gomez C. A., Eldred L. et al. Interventions for seropositive injectors-research and evaluation: an integrated behavioral intervention with HIV-positive injection DU to address medical care, adherence, and risk reduction. J Acquir Immune Defic Syndr 2004 37 : S110 18.
33. Palepu A., Tyndall M., Yip B., O'Shaughnessy M. V., Hogg R. S., Montaner J. S. Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use. J Acquir Immune Defic Syndr 2003 32 : 522 6.
34. Palepu A., Tyndall M. W., Li K., Yip B., O'Shaughnessy M. V., Schechter M. T. et al. Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection DU starting antiretroviral therapy. J Urban Health 2003 80 : 667 75.
35. Clarke S., Delamere S., McCullough L., Hopkins S., Bergin C., Mulcahy F. Assessing limiting factors to the acceptance of antiretroviral therapy in a large cohort of injecting DU. HIV Med 2003 4 : 33 7.
36. Palepu A., Tyndall M. W., Joy R., Kerr T., Wood E., Press N. et al. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection DU: the role of methadone maintenance therapy. Drug Alcohol Depend 2006 84 : 188 94.
37. Knowlton A., Arnsten J., Eldred L., Wilkinson J., Gourevitch M., Shade S. et al. Individual, interpersonal, and structural correlates of effective HAART use among urban active injection DU. J Acquir Immune Defic Syndr 2006 41 : 486 92.
38. Palepu A., Horton N. J., Tibbetts N., Meli S., Samet J. H. Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: the impact of substance abuse treatment. Addiction 2004 99 : 361 8.
39. Waldrop-Valverde D., Valverde E. Homelessness and psychological distress as contributors to antiretroviral nonadherence in HIV-positive injecting DU. AIDS Patient Care STDS 2005 19 : 326 34.
40. Waldrop-Valverde D., Ownby R. L., Wilkie F. L., Mack A., Kumar M., Metsch L. Neurocognitive aspects of medication adherence in HIV-positive injecting DU. AIDS Behav 2006 10 : 287 97.
41. Sharpe T. T., Lee L. M., Nakashima A. K., Elam-Evans L. D., Fleming P. L. Crack cocaine use and adherence to antiretroviral treatment among HIV-infected black women. J Commun Health 2004 29 : 117 27.
42. Liu H., Longshore D., Williams J. K., Rivkin I., Loeb T., Warda U. S. et al. Substance abuse and medication adherence among HIV-positive women with histories of child sexual abuse. AIDS Behav 2006 10 : 279 86.
43. Roca B., Gomez C. J., Arnedo A. Stavudine, lamivudine and indinavir in drug abusing and non-drug abusing HIV-infected patients: adherence, side effects and efficacy. J Infect 1999 39 : 141 5.
44. Moatti J. P., Carrieri M. P., Spire B., Gastaut J. A., Cassuto J. P., Moreau J. Adherence to HAART in French HIV-infected injecting DU: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group. AIDS 2000 14 : 151 5.
45. Bouhnik A. D., Preau M., Vincent E., Carrieri M. P., Gallais H., Lepeu G. et al. Depression and clinical progression in HIV-infected DU treated with highly active antiretroviral therapy. Antivir Ther 2005 10 : 53 61.
46. Carrieri M. P., Chesney M. A., Spire B., Loundou A., Sobel A., Lepeu G. et al. Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting DU. Int J Behav Med 2003 10 : 1 14.
47. Pradier C., Carrieri P., Bentz L., Spire B., Dellamonica P., Moreau J. et al. Impact of short-term adherence on virological and immunological success of HAART: a case study among French HIV-infected IDU. Int J STD AIDS 2001 12 : 324 8.
48. Duran S., Solas C., Spire B., Carrieri M. P., Fuzibet J. G., Costagliola D. et al. Do HIV-infected injecting DU over-report adherence to highly active antiretroviral therapy? A comparison between patients' self-reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study. AIDS 2001 15 : 1075 7.
49. Bouhnik A. D., Chesney M., Carrieri P., Gallais H., Moreau J., Moatti J. P. et al. Nonadherence among HIV-infected injecting DU: the impact of social instability. J Acquir Immune Defic Syndr 2002 31 : S149 53.
50. Kerr T., Marshall A., Walsh J., Palepu A., Tyndall M., Montaner J. et al. Determinants of HAART discontinuation among injection drug users. AIDS Care 2005 17 : 539 49.
51. Palepu A., Tyndall M. W., Chan K., Wood E., Montaner J. S., Hogg R. S. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes. Antivir Ther 2004 9 : 713 19.
52. Kerr T., Palepu A., Barness G., Walsh J., Hogg R., Montaner J. et al. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver. Antivir Ther 2004 9 : 407 14.
53. Martin L. L., Hermandez S. O., Carrobles J. A. Psychosocial variables in the antiretroviral treatment adherence in methadone maintenance patients Psicothema 2005 17 : 575 81 in Spanish I., Campo M., Martin J., Fernandez-Shaw C., Pulido F., Rubio R. Factors affecting patient adherence to highly active antiretroviral therapy. Ann Pharmacother 2003 37 : 775 81.
54. Gordillo V., del Amo J., Soriano V., Gonzalez-Lahoz J. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS 1999 13 : 1763 9.
55. Crisp B. R., Williams M., Timpson S., Ross M. W. Medication compliance and satisfaction with treatment for HIV disease in a sample of African-American crack cocaine smokers. AIDS Behav 2004 8 : 199 206.
56. Lucas G. M., Cheever L. W., Chaisson R. E., Moore R. D. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr 2001 27 : 251 9.
57. Martini M., Recchia E., Nasta P., Castanotto D., Chiaffarino F., Parazzini F. et al. Illicit drug use: can it predict adherence to antiretroviral therapy? Eur J Epidemiol 2004 19 : 585 7.
58. Smith-Rohrberg D., Mezger J., Walton M., Bruce R. D., Altice F. L. Impact of Enhanced services on virologic outcomes in a directly administered antiretroviral therapy trial for HIV-infected DU. J Acquir Immune Defic Syndr 2006 43 : S48 53.
59. Wagner G. J., Ryan G. W. Relationship between routinization of daily behaviors and medication adherence in HIV-positive DU. AIDS Patient Care STDS 2004 18 : 385 93.
60. McCance-Katz E. F., Kosten T. A., Kosten T. R. Going from the bedside back to the bench with ecopipam: a new strategy for cocaine pharmacotherapy development. Psychopharmacology (Berl) 2001 155 : 327 9.
61. Vocci F. J., Acri J., Elkashef A. Medication development for addictive disorders: the state of the science. Am J Psychiatry 2005 162 : 1432 40.
62. Vocci F. J., Elkashef A. Pharmacotherapy and other treatments for cocaine abuse and dependence. Curr Opin Psychiatry 2005 18 : 265 70.
63. Parsons J. T., Rosof E., Punzalan J. C., Di Maria L. Integration of motivational interviewing and cognitive behavioral therapy to improve HIV medication adherence and reduce substance use among HIV-positive men and women: results of a pilot project. AIDS Patient Care STDS 2005 19 : 31 9.
64. van der Werf M. J., Schinkel J., van Santen G., Vergouwe I., Wix R. A., van Ameijden E. J. Highly active antiretroviral therapy among DU in Amsterdam: self-perceived reasons for not receiving therapy. AIDS 1999 13 : 1280 1.
65. Aceijas C., Oppenheimer E., Stimson G. V., Ashcroft R. E., Matic S., Hickman M. Antiretroviral treatment for injecting DU in developing and transitional countries 1 year before the end of the 'Treating 3 million by 2005. Making it happen. The WHO strategy' ('3 by 5'). Addiction 2006 101 : 1246 53.